HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Limited Brands Q3

This article was originally published in The Rose Sheet

Executive Summary

Bath & Body Works comp store sales increased 9% in the third quarter, and net sales grew 9.3% to $350 mil., Limited Brands announces Nov. 18. Beauty retailer's operating income grew 1.3% to $4.6 mil., as anticipated, due to a profit plan that is heavily weighted to the fourth quarter, CEO Neil Fiske says in a conference call with analysts. Holiday plan, which began Oct. 18, is running ahead of expectations, exec notes, adding seasonal business has been up strongly compared to the prior year fueled by a "near doubling of our Perfect Christmas line and seasonal toiletries." Victoria's Secret Beauty sales have been driven by the success of sub-brands, such as Very Sexy for Her and Garden lip gloss, the firm adds. Victoria's Secret comp store sales increased 13%, net sales grew 13.2% to $830 mil., and operating income was up 12.9% to $107.2 mil...

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel